ETFs Harbin Gloria Pharmaceuticals Co., Ltd

002437

CNE100000QG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 2026-10-30			5-day change	1st Jan Change
2.900 ^CNY	+0.69%		-5.84%	-5.54%

10-27	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
08-26	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026	CI

ETFs positioned on Harbin Gloria Pharmaceuticals Co., Ltd

Name	YTD change	Weight	AuM
DIMENSIONAL EMERGING MARKETS CORE EQUITY 2 ETF - USD	+10.16%	-	9,273 M€
DIMENSIONAL WORLD EQUITY ETF - USD	+12.12%	-	1,674 M€
STATE STREET SPDR S&P EMERGING MARKETS SMALL CAP ETF - USD	-0.31%	0.02%	701 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+11.65%	0%	62 M€

HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.

Employees

2,350

Sector

Pharmaceuticals

More about the company